On this page
TMEM43
transmembrane protein 43
TMEM43 encodes a transmembrane protein anchored in the nuclear envelope that maintains structural integrity in cardiac muscle cells. The TMEM43 gene provides instructions for making transmembrane protein 43, a component of the nuclear envelope that plays a critical role in maintaining the structural stability of heart muscle cells.
TMEM43 is located on the short (p) arm of chromosome 3, at band 3p25.1. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 3 in the library →Overview
TMEM43 is located on chromosome 3 and encodes a 400-amino acid protein that resides primarily within the inner nuclear membrane of cells. This protein belongs to a family of transmembrane proteins that contribute to nuclear envelope architecture, the double-membrane barrier separating the nucleus from the cytoplasm. Within cardiac myocytes, TMEM43 appears particularly important for maintaining the mechanical resilience of cells subjected to repeated contraction and relaxation cycles.
Pathogenic changes in TMEM43 are recognised as a cause of arrhythmogenic cardiomyopathy, a progressive cardiac disorder in which normal heart muscle tissue is gradually replaced by fibrofatty scar tissue. This replacement process disrupts the heart's electrical conduction system and mechanical function, predisposing affected individuals to ventricular arrhythmias and structural heart failure. The inheritance pattern follows an autosomal dominant model, meaning a single altered copy of the gene can be sufficient to cause disease. Because of the serious and potentially life-threatening nature of associated cardiac complications, TMEM43 is included in the American College of Medical Genetics and Genomics Secondary Findings list, a set of genes recommended for reporting when pathogenic variants are identified incidentally during genome or exome sequencing, though implementation varies by jurisdiction and laboratory policy.
What the gene does
The protein encoded by TMEM43 is embedded within the inner nuclear membrane, where it contributes to the structural framework that maintains nuclear shape and anchors chromatin to the nuclear periphery. Research suggests that TMEM43 interacts with components of the LINC complex, a molecular assembly that physically connects the nuclear interior to the cytoskeleton outside the nucleus. This connection is thought to facilitate the transmission of mechanical forces across the nuclear envelope, allowing cells to sense and respond to physical stress.
In cardiac muscle cells, which experience continuous mechanical strain during each heartbeat, maintaining nuclear envelope integrity is essential for cell survival. Evidence indicates that TMEM43 plays a role in protecting cardiomyocytes from mechanical stress-induced damage. When the protein functions normally, it helps distribute forces evenly across the nuclear membrane, preventing localised membrane rupture and DNA damage. Studies in cellular models have shown that loss of functional TMEM43 leads to increased nuclear fragility, enhanced susceptibility to mechanical disruption, and activation of cellular stress pathways.
Beyond its structural role, TMEM43 may influence gene expression programmes within the nucleus. Some research indicates that proteins localised to the inner nuclear membrane can modulate the activity of transcription factors and alter chromatin organisation. In the context of cardiac tissue, disruption of these regulatory functions could contribute to abnormal cell differentiation and the pathological remodelling observed in cardiomyopathy. The precise molecular mechanisms by which TMEM43 influences cardiac gene expression remain an active area of investigation, but current evidence supports a model in which structural integrity and transcriptional regulation are intimately linked at the nuclear envelope.
The protein appears to function as part of a larger network of nuclear envelope proteins, and its loss or dysfunction may compromise the stability of this entire network. This interdependence helps explain why TMEM43 variants can have profound effects on cardiac tissue despite the protein being expressed in many cell types throughout the body. Cardiac myocytes, with their unique mechanical demands and limited regenerative capacity, may be particularly vulnerable to disruptions in nuclear envelope homeostasis.
Video: Genetics 101
Chromosome location
TMEM43 is located on the short arm of chromosome 3 at position 25.1, designated as 3p25.1. The gene spans a genomic region that includes multiple exons encoding the 400-amino acid protein product. This chromosomal region has been mapped in detail through both physical and genetic studies, allowing precise localisation of disease-associated variants.
The 3p25 region contains several other genes involved in diverse cellular functions, but TMEM43 stands out for its specific role in cardiac pathology. The gene's genomic structure has been fully characterised, facilitating the development of targeted sequencing approaches used in clinical genetic testing for cardiomyopathy. Identification of the precise chromosomal location has also enabled population-based studies examining the frequency of TMEM43 variants across different ethnic and geographic groups.
Protein structure
High-resolution domain architecture has not yet been experimentally determined for this protein. Transmembrane protein 43 is predicted to contain multiple membrane-spanning segments that anchor it within the lipid bilayer of the inner nuclear membrane, but detailed structural data defining discrete functional domains remain limited. Computational analyses suggest the presence of transmembrane helices that traverse the membrane, with portions of the protein extending into both the nuclear interior and the space between the inner and outer nuclear membranes.
The absence of well-defined functional domains in current annotations does not diminish the protein's importance. Many nuclear envelope proteins lack classical modular domains yet perform essential structural roles through extended regions that mediate protein-protein interactions or membrane anchoring. In the case of TMEM43, the transmembrane segments themselves likely represent the most critical structural features, positioning the protein appropriately to interact with both nuclear and cytoplasmic partners.
Future crystallographic or cryo-electron microscopy studies may reveal additional structural details that clarify how TMEM43 integrates into the nuclear envelope and interacts with other components of the nuclear lamina and LINC complex.
Key variants
Pathogenic variants in TMEM43 have been identified predominantly in families with arrhythmogenic cardiomyopathy, with certain variants showing founder effects in specific populations. The variant landscape includes missense changes, small deletions, and insertions that disrupt protein function through different mechanisms. Some variants appear to interfere with proper localisation of the protein to the nuclear membrane, while others may compromise its structural integrity or ability to interact with binding partners.
One particular variant (p.Ser358Leu) has been extensively studied in families of Newfoundland ancestry, where it is associated with substantial penetrance and a characteristic pattern of cardiac involvement. Genetic studies in this population have provided valuable insights into genotype-phenotype correlations and the natural history of TMEM43-associated cardiomyopathy. Beyond this founder variant, additional pathogenic changes have been reported in diverse populations, expanding the known mutation spectrum and highlighting the gene's importance across different genetic backgrounds.
The penetrance and expressivity of TMEM43 variants can vary, with some individuals developing severe cardiac disease in early adulthood while others may remain asymptomatic until later in life. Factors influencing this variability likely include genetic modifiers, sex, lifestyle factors, and environmental exposures, though the relative contribution of each remains incompletely understood.
Sample of pathogenic variants
3 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.1073C>T | p.Ser358Leu | Pathogenic | ★★☆☆ | TMEM43-related disorder |
c.201dup | p.Leu68fs | Likely pathogenic | ★☆☆☆ | Emery-Dreifuss muscular dystrophy 7, autosomal dominant |
c.393-2A>G | - | Likely pathogenic | ★☆☆☆ | Arrhythmogenic right ventricular dysplasia 5 |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Pathogenic variants in TMEM43 are primarily associated with arrhythmogenic cardiomyopathy, a progressive disorder affecting the heart muscle. This condition is characterised by fibrofatty replacement of ventricular myocardium, particularly affecting the right ventricle, although left ventricular involvement is also recognised. The disease typically manifests with ventricular arrhythmias, which can range from isolated premature ventricular contractions to sustained ventricular tachycardia and ventricular fibrillation.
Individuals with TMEM43-associated cardiomyopathy may present with palpitations, syncope, chest pain, or dyspnoea, though some remain asymptomatic until a life-threatening arrhythmic event occurs. The progressive nature of the disease means that structural abnormalities may worsen over time, leading to heart failure in advanced cases. Diagnostic evaluation typically includes electrocardiography, Holter monitoring, echocardiography, and cardiac magnetic resonance imaging to assess both electrical and structural features of the heart. The identification of a pathogenic TMEM43 variant can inform clinical management, including decisions regarding implantable cardioverter-defibrillator placement and restriction from competitive athletics.
No disease links recorded for this gene in our reference set.
Inheritance pattern
Conditions caused by pathogenic TMEM43 variants typically follow autosomal dominant inheritance.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
UK clinical status
Within the UK National Health Service Genomic Medicine Service, TMEM43 is included on multiple clinical gene panels used for the diagnosis and management of inherited cardiac conditions. The gene holds green classification status on the Arrhythmogenic Right Ventricular Cardiomyopathy panel (R133), indicating strong evidence supporting its role in this specific condition. It also appears on the Dilated and Arrhythmogenic Cardiomyopathy panel (R132) and the Paediatric or Syndromic Cardiomyopathy panel (R135), reflecting its relevance across the spectrum of inherited heart muscle disorders.
These panel memberships guide which genes are analysed when individuals with suspected cardiomyopathy undergo genetic testing through NHS genomic services. Green classification signifies a high level of confidence in the gene-disease association based on published evidence and expert review. Clinicians requesting genetic testing for patients with arrhythmogenic features or dilated cardiomyopathy can expect TMEM43 to be included in the standard testing pathway, facilitating timely diagnosis and enabling cascade screening of at-risk family members.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Diet & lifestyle considerations
For individuals with pathogenic TMEM43 variants, current clinical guidance generally recommends avoidance of intense competitive sports and strenuous exercise, as vigorous physical activity may accelerate disease progression and increase arrhythmia risk in arrhythmogenic cardiomyopathy. Research in related forms of cardiomyopathy suggests that high-intensity endurance training can exacerbate fibrofatty replacement of the myocardium in genetically predisposed individuals. While moderate recreational physical activity is often considered acceptable under medical supervision, decisions about appropriate exercise levels should be individualised based on cardiac imaging findings, arrhythmia burden, and the advice of a specialist cardiologist.
Dietary considerations for individuals with cardiomyopathy typically align with general heart-healthy recommendations, including limitation of sodium intake to reduce fluid retention, moderation of alcohol consumption, and maintenance of a balanced diet rich in fruits, vegetables, whole grains, and lean proteins. Some evidence from broader cardiovascular research indicates that omega-3 fatty acids may have anti-arrhythmic properties, though no studies have specifically examined dietary interventions in TMEM43 variant carriers. Any significant dietary modifications should be discussed with a healthcare provider familiar with the individual's cardiac status.
Weight management may also be relevant, as obesity can place additional strain on the heart and complicate the management of heart failure symptoms. However, weight loss strategies should be implemented cautiously and under medical guidance, particularly if exercise restrictions are in place. Smoking cessation is strongly advised for all individuals with cardiac conditions, as tobacco use increases arrhythmia risk and contributes to overall cardiovascular disease burden.
Supplement considerations
There is currently no conclusive evidence that any specific dietary supplement can prevent or slow the progression of TMEM43-associated arrhythmogenic cardiomyopathy. While some individuals may consider supplements such as coenzyme Q10, omega-3 fatty acids, or magnesium based on their potential cardiovascular benefits in other contexts, these agents have not been rigorously studied in the setting of genetically determined cardiomyopathy caused by nuclear envelope protein dysfunction.
Coenzyme Q10 is sometimes used in heart failure management, and small studies have suggested potential benefits for certain cardiomyopathy subtypes, but evidence specific to TMEM43-related disease is absent. Similarly, omega-3 fatty acid supplementation has shown mixed results in studies of arrhythmia prevention across various cardiac conditions, but these findings cannot be extrapolated to TMEM43-related disease. Magnesium supplementation is occasionally recommended for individuals with documented deficiency or certain arrhythmias, but routine supplementation in the absence of deficiency has not been proven beneficial for inherited cardiomyopathies.
Anyone considering supplement use should discuss this with their cardiologist or general practitioner before beginning any new regimen, as some supplements may interact with prescribed cardiac medications or carry risks in specific clinical contexts. The foundation of management for TMEM43-associated cardiomyopathy remains regular cardiac surveillance, appropriate use of antiarrhythmic medications or implantable devices, and adherence to exercise recommendations rather than supplementation strategies.
Frequently asked questions
What is the role of TMEM43 in the heart?
TMEM43 encodes a protein located in the nuclear envelope of cardiac muscle cells, where it helps maintain structural integrity during the mechanical stress of repeated heart contractions. Research suggests this protein is particularly important for protecting heart muscle cells from damage and maintaining normal tissue architecture.
How is TMEM43-associated cardiomyopathy inherited?
TMEM43-associated cardiomyopathy follows an autosomal dominant inheritance pattern, meaning that inheriting one altered copy of the gene from either parent can be sufficient to cause the condition. Each child of an affected individual has a 50% chance of inheriting the variant.
Why is TMEM43 included in secondary findings recommendations?
TMEM43 is included in the ACMG Secondary Findings list because pathogenic variants in this gene can cause serious, potentially life-threatening cardiac arrhythmias, and early identification enables interventions such as implantable cardioverter-defibrillator placement and family screening that may prevent sudden cardiac death.
Can TMEM43 variants affect organs other than the heart?
While TMEM43 is expressed in various tissues throughout the body, the cardiac manifestations of pathogenic variants are the predominant clinical feature. Some research has investigated whether nuclear envelope dysfunction might affect other organs, but arrhythmogenic cardiomyopathy remains the primary recognised consequence of TMEM43 variants.
What type of cardiac monitoring is recommended for TMEM43 variant carriers?
Individuals with pathogenic TMEM43 variants typically require regular cardiac evaluation including electrocardiograms, echocardiography, and often Holter monitoring or cardiac magnetic resonance imaging to detect early signs of structural changes or arrhythmias. The specific monitoring schedule should be determined by a cardiologist based on individual clinical features.
Are there any treatments specific to TMEM43-associated cardiomyopathy?
Treatment focuses on managing arrhythmias and heart failure symptoms rather than targeting the underlying genetic cause. Management strategies may include antiarrhythmic medications, beta-blockers, implantable cardioverter-defibrillators, exercise restriction, and in advanced cases, heart transplantation. Treatment plans should be individualised by a specialist in inherited cardiac conditions.